MetaCap

U.S. Physical Therapy (USPH) vs GeneDx (WGS)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

U.S. Physical Therapy (USPH) has outperformed GeneDx (WGS) over the past year, gaining 33.9% versus a loss of 69.0%. Over five years, USPH leads with a +8.3% price change compared with -80.0% for WGS. U.S. Physical Therapy is the larger company by market cap ($1.43 billion vs $1.36 billion), about 1.1 times the size, while GeneDx is growing revenue faster (+40.0% vs +16.3%).

On valuation, U.S. Physical Therapy trades at a lower forward P/E (28.5x vs 34.9x for GeneDx). U.S. Physical Therapy pays a dividend yielding 1.91%, while GeneDx does not currently pay one. U.S. Physical Therapy converts more of its revenue into profit, with a net margin of 5.1% versus -4.9%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

USPH+33.92%WGS-68.98%
+46%-18%-82%
Nov 21, 20251 yearNov 20, 2026
USPH+5.32%WGS-81.08%
+50%-28%-107%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

USPH versus WGS key metrics
MetricUSPHWGS
Share price$95.93$45.46
Market cap$1.43B$1.36B
1-day change+1.71%-7.68%
YTD return+22.85%-65.05%
1-year return+33.92%-68.98%
5-year return+8.32%-80.01%
Forward P/E28.5034.93
EPS (TTM)$-1.33$-3.76
Dividend yield1.91%0.00%
Annual dividend$1.83$0.00
Revenue (latest FY)$780.99M$427.54M
Revenue growth (YoY)+16.33%+39.97%
Net income (latest FY)$39.58M$-21.02M
Gross margin19.17%69.74%
Operating margin11.10%-3.06%
Net margin5.07%-4.92%
52-week high$101.80$170.87
52-week low$58.19$32.21
Distance from 52-week high-5.77%-73.39%
Analyst consensusbuystrong_buy
Avg. price target upside+16.23%+80.38%
Average volume186.22K869.34K
Shares outstanding14.93M29.97M
Employees4,6531,300
SectorHealth CareHealth Care
IndustryMedical/Nursing ServicesMedical/Nursing Services

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • USPH has outperformed WGS by 102.9 percentage points over the past year.
  • U.S. Physical Therapy offers a meaningfully higher dividend yield (1.91% vs 0.00%).
  • U.S. Physical Therapy is more profitable, keeping 5.1 cents of every revenue dollar as net income versus -4.9 cents for GeneDx.
  • GeneDx grew revenue faster in its latest fiscal year (+39.97% vs +16.33%).

About U.S. Physical Therapy

USPH stock →

U.S. Physical Therapy, Inc., together with its subsidiaries, operates and manages outpatient physical therapy clinics.

Health Care · Medical/Nursing Services · 4,653 employees

About GeneDx

WGS stock →

GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services.

Health Care · Medical/Nursing Services · 1,300 employees

USPH vs WGS FAQ

Which is bigger, U.S. Physical Therapy or GeneDx?

U.S. Physical Therapy (USPH) is larger, with a market capitalization of $1.43B compared with $1.36B for GeneDx (WGS).

Which stock has performed better over the past year, USPH or WGS?

USPH returned +33.92% over the past 12 months, compared with -68.98% for WGS (price return, excluding dividends). Past performance does not predict future results.

Which pays a higher dividend, U.S. Physical Therapy or GeneDx?

U.S. Physical Therapy pays a dividend yielding 1.91%, while GeneDx does not currently pay a regular dividend.

Are U.S. Physical Therapy and GeneDx in the same industry?

Yes. Both are classified in the Medical/Nursing Services industry within the Health Care sector.

More comparisons